A Phase 3 trial, randomized, open-label, 2-period crossover study to evaluate the safety and efficacy of SHP655 in the treatment and prevention of acute TTP events in patients with severe hereditary ADAMTS13 deficiency.

Trial Profile

A Phase 3 trial, randomized, open-label, 2-period crossover study to evaluate the safety and efficacy of SHP655 in the treatment and prevention of acute TTP events in patients with severe hereditary ADAMTS13 deficiency.

Planning
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs BAX 930 (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top